CureMatch Tsigelny Presents at PCS 4th Annual Global Cancer Conference
LISBON, PORTUGAL – CureMatch is proud to announce that CureMatch Chief Technology Officer and co-founder, Igor Tsigelny, PhD was invited in November as a plenary speaker to the PCS 4th Annual Global Cancer Conference-2017 in Lisbon, Portugal.
The international meeting focused on basic research and clinical cancer research. Presentations and discussions concerning top cancer killers and treatment options prompted partnerships and sparked new ideas for future innovative cancer treatments and standard of care.
Dr. Tsigelny was the chair of the keynote session, and presented a paper detailing CureMatch’s approach to clinical decision support in oncology. The abstract is attached below:
Title: Personalized Cancer Medicine: System for Physician Decision Support
Dr. Igor F. Tsigelny 1,2 (GCC), Boichard, A 1,2, Richard, S 1, Kurzrock, R 2
1 CureMatch Inc., USA
2 University of California, USA
We present the new decision-support system for personalized medicine. This system is developed at CureMatch (San Diego) . It is an interactive tool helping physicians to review possible therapeutic options in cancer treatment based on genomic, proteomic, and other profiles of patients. Our system takes in consideration activities and toxicities of drugs, uses proprietary rule-based system to address gene aberrations with optimal combinations of drugs. Priority is given to combinations of drugs covering the highest number of targets and using a minimal number of drugs. Optimal combinations usually present the highest Matching Score. Combinations that include approved drugs and on-label are presented ahead of those that include approved but off-label drugs. The system allows the user to set up additional criteria, such as the use of ‘mandatory’ drugs or the eviction of ‘unwanted’ drugs. Therefore, the initial input may be modified at any time, and such updates may result in updated outputs. The system will report known drug-drug interactions as well. Our system also recommends immunotherapies. When relevant (i.e. when the molecular profile includes a marker of response for immunotherapy), immunotherapies are proposed alone or in combination with any additional drug of interest.
Note, that there are now specific response and resistance markers that have been published for immunotherapy and these can be ascertained from genomic profiling ( e.g., microsatellite instability, PD-Ll amplification, high tumor mutational burden etc.) and/or immunohistochemistry tests (PD-Ll tumor positivity).
Igor F. Tsigelny Co-founder and Chief Technology Officer at CureMatch Inc. and Professor of University of California, San Diego.
He is a leading expert in structural biology, molecular modeling, bioinformatics, and structure-based drug design. Dr. Tsigelny published more than 200 papers in scientific journals, co-authored and edited 4 scientific books. He has around 15 existing and pending patents. His computational study of molecular mechanisms of Parkinson’s disease has been included in the US Department of Energy publication “Decade of Discovery” where the best computational studies of the decade 1999-2009 have been described.
The Interests of Research and Collaboration: CureMatch, Inc., based in San Diego, is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/ AIDS, and is considered by many to be the future of cancer treatment. CureMatch’s report guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient’s own tumor. The CureMatch technology has a foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com.